The Pennant Group delivered a first quarter that exceeded Wall Street’s expectations, driven by robust organic momentum and the effective integration of recent acquisitions. Management attributed the strong performance to a combination of leadership development, disciplined margin management, and the successful onboarding of 36 new operations since early 2024. CEO Brent Guerisoli highlighted that both the Home Health and Hospice and Senior Living segments contributed to the growth, with local leadership programs enabling above-trend operational execution and improved clinical results. As Guerisoli emphasized, “Our local CEOs and other C-level leaders earn this designation by demonstrating true ownership and creating clinical, financial, and cultural value.”
Is now the time to buy PNTG? Find out in our full research report (it’s free).
The Pennant Group (PNTG) Q1 CY2025 Highlights:
- Revenue: $209.8 million vs analyst estimates of $201.5 million (33.7% year-on-year growth, 4.1% beat)
- Adjusted EPS: $0.27 vs analyst estimates of $0.24 (13.7% beat)
- Adjusted EBITDA: $16.37 million vs analyst estimates of $14.22 million (7.8% margin, 15.2% beat)
- Operating Margin: 6%, in line with the same quarter last year
- Sales Volumes rose 28.9% year on year (34.3% in the same quarter last year)
- Market Capitalization: $1 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions The Pennant Group’s Q1 Earnings Call
- Stephen Baxter (Wells Fargo) asked about the reacceleration of same-store growth in Home Health and Hospice. President John Gochnour attributed Q1’s improvement to post-holiday seasonality, noting ongoing double-digit growth in core metrics.
- Stephen Baxter (Wells Fargo) requested more detail on which business segments contributed most to guidance outperformance. CEO Brent Guerisoli stated that both Home Health and Hospice and Senior Living performed well, with outsized progress in recent acquisitions like Signature Healthcare.
- Stephen Baxter (Wells Fargo) inquired about the strategic rationale for the pending UnitedHealth-Amedisys transaction. Guerisoli emphasized that leadership capacity and asset quality are key criteria, but declined further details due to ongoing regulatory processes.
- Stephen Baxter (Wells Fargo) questioned the sustainability of pricing strength in Senior Living amid macro uncertainty. Guerisoli noted ongoing efforts to improve revenue quality and leverage state programs, balancing rate increases with occupancy goals.
- Stephen Baxter (Wells Fargo) asked about trends in hiring and labor costs. Gochnour cited strong nurse hiring and retention but acknowledged ongoing labor cost inflation, particularly in Senior Living, as an ongoing operational focus.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will be watching (1) execution and financial performance from integrating new acquisitions, especially Signature Healthcare and any assets from the UnitedHealth-Amedisys transaction; (2) the trend in labor costs and continued nurse retention in both business segments; and (3) whether Senior Living can achieve occupancy gains without sacrificing revenue quality. Sustained momentum in organic growth and clinical outcomes will also be important markers.
The Pennant Group currently trades at $28.34, up from $26.89 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.